Kasraian Kasra sold $2K of PEPG

Kasraian Kasra (Chief Technical Officer) sold 1,233 shares of PepGen Inc. (PEPG) at $1.41 on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kasraian Kasra
Published May 26, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PEPG
Neutral
medium confidence
Mentioned
$PEPG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PEPGNeutralLow
01

Why it matters

The disclosure may cause short-lived sentiment noise, but the pre-arranged 10b5-1 designation generally lowers the probability that the sale reflects new, material negative information.

02

Market read

A small, pre-planned insider sale is unlikely to drive a durable move absent other catalysts.

03

What to watch

The filing does not state motives; traders should check for pattern frequency across prior Form 4s and whether sales cluster around volatility or financing/news windows.

Relevance 6/10Timing: Immediate for monitoring/positioning around the filing date; not a catalyst for fundamental repricing.

Background

This is an SEC Form 4 insider transaction by PepGen’s Chief Technical Officer, disclosed via EDGAR.

Company-level read

Ticker impact

$PEPGNeutralMedium confidence
Context

PepGen CTO Kasraian Kasra filed an open-market sale of 1,233 shares at $1.4107 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small and fade unless accompanied by other fundamental news.

Evidence & confidence

Form 4 shows a modest dollar value transaction ($1,739) and indicates a pre-arranged 10b5-1 plan, which often reflects routine liquidity rather than new negative information.

Market effects

Minimal; this is company-specific insider liquidity disclosure rather than a sector-wide development.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially in thinly traded small caps.

Key entities

  • PepGen Inc.

    Subject of the Form 4 insider sale by its CTO under a pre-arranged 10b5-1 plan.

  • Kasraian Kasra

    Chief Technical Officer who sold 1,233 shares of PEPG at $1.4107/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PEPGHighAI 9/10

Why is PepGen stock surging today?

PepGen's stock surged 125.1% in pre-market trading after reporting positive Phase 2 trial results for PGN-EDODM1, showing significant efficacy in treating myotonic dystrophy type 1. The company also reported $104.8M in cash for operations into 2028. CEO James McArthur expressed confidence in the asset's potential. The S&P 500 and Dow Jones rose slightly, while the Nasdaq dipped ahead of the October CPI report.

$PEPGHigh

PepGen Reports Third Quarter 2026 Financial Results

PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights – Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enro

$PEPGMedAI 8/10

PepGen reports splicing correction results in DM1 trial

PepGen Inc. (PEPG) reported Phase 2 trial results for PGN-EDODM1 in myotonic dystrophy type 1 patients. The 10 mg/kg cohort showed 46.5% mean splicing correction, with improvements in myotonia, grip strength, and mobility tests. No severe adverse events were reported. The 12.5 mg/kg cohort is fully enrolled, with results expected in 2027.

$PEPGMedAI 8/10

PepGen (PEPG) Reports Positive Phase 2 Results at 10 mg/kg

PepGen (PEPG) reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial. The 12.5 mg/kg cohort is fully enrolled, but no specific efficacy or safety data were provided. The company's PGN-EDODM1 program is in early clinical stages, and further updates may impact investor sentiment.